

**Anti-D immunoglobulin**

Section	Indications
Human immunoglobulins Parenteral > General injections > IV: 250 µg in single-dose vial Parenteral > General injections > IM: 250 µg in single-dose vial	Maternal care for red cell antibodies

**Carbetocin**

Section	Indications
Uterotonics Parenteral > General injections > IV: 100 µg per mL (heat stable)	Postpartum haemorrhage

**Carboplatin**

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL	Other specified carcinomas of ovary

**Cisplatin**

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL	Malignant neoplasms of cervix uteri

**Clomifene**

Section	Indications
Ovulation inducers Oral > Solid: 50 mg (citrate)	Female infertility without specification whether primary or secondary

**Copper-containing intrauterine device**

Section	Indications
Intrauterine devices -	Contact with health services for insertion of contraceptive device

## Dexamethasone

### Section

Other medicines administered to the mother  
Parenteral > General injections > unspecified: 4 mg per mL  
(dexamethasone phosphate (as sodium))

### Indications

Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

## Ergometrine

### Section

Uterotonics  
Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule  
(hydrogen maleate)

### Indications

Postpartum haemorrhage

## Estradiol cypionate + medroxyprogesterone acetate

### Section

Injectable hormonal contraceptives  
Parenteral > General injections > IM: 5 mg + 25 mg

### Indications

Contact with health services for reasons associated with reproduction

## Ethinylestradiol + etonogestrel

### Section

Intravaginal contraceptives  
Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

### Indications

Contact with health services for contraceptive management

## Ethinylestradiol + levonorgestrel

### Section

Oral hormonal contraceptives  
Oral > Solid: 50 µg + 250 µg [4]  
Oral > Solid: 30 µg + 150 µg

### Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

## Ethinylestradiol + norethisterone

### Section

Oral hormonal contraceptives  
Oral > Solid: 35 µg + 1 mg

### Indications

Contact with health services for contraceptive management

## Etonogestrel-releasing implant

### Section

Implantable contraceptives

Implant > Subdermal: 68 mg single rod

### Indications

Contact with health services for insertion of contraceptive device

## Folic acid

### Section

Antianaemia medicines

Oral > Solid: 400 µg

### Indications

Anencephaly or similar anomalies

Spina bifida

Cephalocele

## Levonorgestrel

### Section

Oral hormonal contraceptives

Oral > Solid: 750 µg [2]; 1.5 mg [1]

Oral > Solid: 30 µg

Intrauterine devices

Intrauterine system with reservoir containing 52 mg of levonorgestrel.

### Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Contact with health services for insertion of contraceptive device

## Levonorgestrel-releasing implant

### Section

Implantable contraceptives

Implant > Subdermal: 75 mg per rod (two-rods)

### Indications

Contact with health services for insertion of contraceptive device

## Medroxyprogesterone acetate

### Section

Injectable hormonal contraceptives

Parenteral > General injections > IM: 150 mg per mL in 1 mL vial

Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system

Progestogens

Oral > Solid: 5 mg

### Indications

Contact with health services for reasons associated with reproduction

Excessive menstruation with irregular cycle

## Methyldopa

### Section

Antihypertensive medicines

Oral > Solid: 250 mg

### Indications

Gestational hypertension

## Methylergometrine

### Section

Uterotonics

### Indications

Therapeutic equivalent to [ergometrine](#) for

Postpartum haemorrhage

## Mifepristone - misoprostol

### Section

Uterotonics

Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package

### Indications

Induced abortion

Unspecified time of fetal death, cause not specified

## Misoprostol

### Section

Uterotonics

Oral > Solid: 200 µg

Local > Vaginal > tablet: 25 µg

### Indications

Spontaneous abortion, incomplete, without complication

Unspecified obstetric condition

Postpartum haemorrhage

## Multiple micronutrient supplement

### Section

Other medicines administered to the mother

Tablet containing:

Vit A: 800 mcg retinol activity equivalent

Vit C: 70 mg

Vit D: 5 mcg (200 IU)

Vit E: 10 mg alpha tocopherol equivalent

Vit B1: 1.4 mg

Vit B2: 1.4 mg

Vit B3: 18 mg niacin equivalent

Vit B6: 1.9 mg

Folic acid: 400 mcg

Vit B12: 2.6 mcg

Iron: 30 mg

Iodine: 150 mcg

Zinc: 15 mg

Selenium: 65 mcg

Copper: 2 mg

### Indications

Maternal care for other specified conditions predominantly related to pregnancy

## Nifedipine

### Section

Antioxytocics (tocolytics)

Oral > Solid: 10 mg (immediate-release)

### Indications

Preterm labour without delivery

## Norethisterone

### Section

Oral hormonal contraceptives

Oral > Solid: 350 µg

Progestogens

### Indications

Contact with health services for contraceptive management

Therapeutic equivalent to medroxyprogesterone acetate for

Excessive menstruation with irregular cycle

## Norethisterone enantate

### Section

Injectable hormonal contraceptives

Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

### Indications

Contact with health services for reasons associated with reproduction

## Oxytocin

### Section

Uterotonics

Parenteral > General injections > unspecified: 10 IU per mL

### Indications

Postpartum haemorrhage

## Progesterone vaginal ring

### Section

Intravaginal contraceptives

Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

### Indications

Contact with health services for contraceptive management

## Simvastatin

### Section

Medicines for endocrine disorders

Oral > Solid: 20 mg

### Indications

Polycystic ovary syndrome

## Sulfadoxine + pyrimethamine

### Section

Antimalarial medicines > For chemoprevention

Oral > Solid: 500 mg + 25 mg tablet

### Indications

Malaria due to Plasmodium falciparum

## Tranexamic acid

### Section

Other medicines administered to the mother

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

### Indications

Postpartum haemorrhage

## Ulipristal

### Section

Oral hormonal contraceptives

Oral > Solid: 30 mg tablet (ulipristal acetate)

### Indications

Contact with health services for postcoital contraception